Doxepin vs. Trazodone: Sleep Medication Comparison for PI Cases

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 8 min read

Doxepin (Silenor) and trazodone are non-controlled medications commonly prescribed for injury-related insomnia in personal injury cases. This comparison covers their mechanisms, dosing strategies, and pharmacy lien significance.

Low-dose doxepin is an FDA-approved insomnia treatment that works through histamine receptor antagonism, while trazodone is a serotonin antagonist/reuptake inhibitor used off-label as the most commonly prescribed sleep medication in the United States. Both are non-controlled alternatives to scheduled hypnotics, and their presence in a personal injury pharmacy lien record documents sleep disruption being managed without the dependency risks associated with benzodiazepines or Z-drugs.

• Doxepin at low doses (3-6 mg as Silenor) is FDA-approved for insomnia characterized by difficulty with sleep maintenance
• Trazodone is prescribed off-label for insomnia at doses of 25-100 mg, well below its antidepressant dosing range
• Neither medication is a DEA-scheduled controlled substance, making both attractive options for PI patients on concurrent opioids
• Trazodone is the single most frequently prescribed sleep medication in the United States despite lacking an FDA insomnia indication
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report documenting insomnia treatment rationale within the injury timeline

Mechanism of Action

Doxepin is a tricyclic antidepressant that, at the low doses used for insomnia (3-6 mg), functions primarily as a highly selective histamine H1 receptor antagonist. At these sub-antidepressant doses, doxepin's antihistaminic effect predominates, producing sleep maintenance improvement without the anticholinergic, noradrenergic, and serotonergic effects seen at higher antidepressant doses (75-300 mg). This selectivity at low doses gives Silenor a cleaner pharmacological profile for insomnia than most other repurposed antidepressants.

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI). At low doses used for sleep, trazodone's primary mechanism is antagonism at serotonin 5-HT2A receptors and histamine H1 receptors, both of which promote sedation. It also has alpha-1 adrenergic blocking activity that contributes to drowsiness. At sleep-promoting doses (25-100 mg), the serotonin reuptake inhibition that produces its antidepressant effect at higher doses (150-400 mg) is minimal.

Side-by-Side Comparison

Clinical Significance for Personal Injury

Insomnia following personal injury is pervasive and significantly impairs recovery. Pain disrupts sleep architecture. PTSD produces hyperarousal that prevents sleep onset. Anxiety causes nocturnal rumination. Medications themselves (particularly opioids) can paradoxically fragment sleep. The prescribing of a dedicated sleep medication documents that the treating provider identified clinically significant insomnia requiring pharmacological intervention beyond the sedating side effects of existing medications.

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "Both doxepin and trazodone provide documented evidence of injury-related insomnia on the pharmacy lien. Their non-controlled status is particularly important in PI cases because it shows the prescriber is managing sleep disruption responsibly, without adding controlled substance burden to patients who may already be on opioid analgesics."

Trazodone is the more commonly encountered agent in PI pharmacy records due to its long clinical history, low cost as a generic, and physician familiarity. Doxepin at its FDA-approved Silenor doses represents a more targeted prescribing decision and may appear in cases where the physician specifically wants an FDA-approved insomnia indication for documentation purposes or where sleep maintenance (rather than sleep onset) is the primary complaint.

Prescribing Patterns in PI Context

Doxepin (Silenor) is preferred when:

• Sleep maintenance is the primary complaint (middle-of-night or early-morning awakenings)
• An FDA-approved insomnia indication is desired for documentation strength
• The patient needs a medication with minimal next-day hangover effect (low doses of doxepin have short duration of action)
• Other medications with anticholinergic effects need to be minimized

Trazodone is preferred when:

• The patient has concurrent mild depressive symptoms (low-dose trazodone may provide modest mood benefit)
• Sleep onset difficulty is the primary complaint (trazodone's onset is typically faster)
• The patient needs a medication with extensive clinical experience data
• Cost is a consideration (trazodone generic is widely available)
• The patient is already on an SSRI and the prescriber wants to avoid adding a TCA

Concurrent Use with Pain and Psychiatric Medications

Both medications interact with common PI medication regimens:

Doxepin at low doses has minimal drug interactions due to its selective antihistaminic mechanism. However, at higher doses or in patients with slow CYP2D6 metabolism, TCA-class effects can emerge, requiring caution with concurrent serotonergic agents.

Trazodone carries serotonin syndrome risk when combined with SSRIs, SNRIs, or tramadol, though this risk is considered low at sleep-promoting doses. Its alpha-1 blocking activity can potentiate orthostatic hypotension from other medications. The rare but serious side effect of priapism should be disclosed to male patients.

The pharmacy record documenting these medications alongside pain and psychiatric agents demonstrates a comprehensive, multi-system approach to injury management that supports case complexity and valuation.

Related Resources

• Doxepin (Silenor) for Sleep in Personal Injury
• Trazodone for Sleep Disruption After Injury
• Doxepin vs. Zolpidem for Sleep in PI
• Trazodone vs. Zolpidem for Sleep in PI